Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Gut Ruminococcaceae levels at baseline correlate with risk of antibiotic-associated diarrhea

Gut Ruminococcaceae levels at baseline correlate with risk of antibiotic-associated diarrhea

Thumbnail Image
Download
Name

1-s2.0-S258900422101614X-main.pdf

Description
Published version
Size

3.42 MB

Format

Adobe PDF

Checksum (MD5)

15b0cea67088c5f3e04e5d862d5e7e37

sword-2023-01-26T14:08:58.original.xml (130 B)
Original SWORD entry document
Author(s)
Gu, Xiaoqiong
•
Sim, Jean XY
•
Lee, Wei Lin
•
Cui, Liang
•
Chan, Yvonne FZ
•
Chang, Ega Danu
•
Teh, Yii Ean
•
Zhang, An-Ni
•
Armas, Federica
•
Chandra, Franciscus
more
Date Issued
2022
Journal
iScience
Publisher
Elsevier BV
Citation
Gu, Xiaoqiong, Sim, Jean XY, Lee, Wei Lin, Cui, Liang, Chan, Yvonne FZ et al. 2022. "Gut Ruminococcaceae levels at baseline correlate with risk of antibiotic-associated diarrhea." iScience, 25 (1).
Version
Final published version
Abstract
Antibiotic-associated diarrhea (AAD) affects a significant proportion of patients receiving antibiotics. We sought to understand if differences in the gut microbiome would influence the development of AAD. We administered a 3-day course of amoxicillin-clavulanate to 30 healthy adult volunteers, and analyzed their stool microbiome, using 16S rRNA gene sequencing, at baseline and up to 4 weeks post antibiotic administration. Lower levels of gut Ruminococcaceae were significantly and consistently observed from baseline until day 7 in participants who developed AAD. Overall, participants who developed AAD experienced a greater decrease in microbial diversity. The probability of AAD could be predicted based on qPCR-derived levels of Faecalibacterium prausnitzii at baseline. Our findings suggest that a lack of gut Ruminococcaceae influences development of AAD. Quantification of F. prausnitzii in stool prior to antibiotic administration may help identify patients at risk of AAD, and aid clinicians in devising individualized treatment regimens to minimize such adverse effects.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/147718
DOI of Published Version
https://doi.org/10.1016/J.ISCI.2021.103644
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.